
Renata Sano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2217467/publications.pdf Version: 2024-02-01



RENATA SANO

#	Article	IF	CITATIONS
1	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discovery, 2016, 6, 96-107.	9.4	144
2	Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell, 2016, 29, 159-172.	16.8	104
3	Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. Clinical Cancer Research, 2016, 22, 948-960.	7.0	86
4	Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases. Cell Death and Disease, 2018, 9, 328.	6.3	84
5	Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against Neuroblastoma. Clinical Cancer Research, 2017, 23, 2856-2868.	7.0	76
6	An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Science Translational Medicine, 2019, 11, .	12.4	44
7	Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i> -amplified Neuroblastoma. Molecular Cancer Therapeutics, 2021, 20, 1400-1411.	4.1	10